MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
MaxCyte, Inc. beats earnings expectations. Reported EPS is $-0.05, expectations were $-0.1. MaxCyte, Inc.
Maxcyte Inc. (MXCT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Cadian Capital Eric Bannasch | 5,644,898 | $26,531,021 | 1.05% | |
| 2. | Millennium Management Israel Englander | 5,012,283 | $23,557,730 | +31% | 0.01% |
| 3. | Portolan Capital Management George Mccabe | 2,757,249 | $12,959,070 | +29% | 1.13% |
| 4. | Roubaix Capital Christopher Hillary | 386,201 | $1,815,145 | 1.27% | |
| 5. | Royce & Associates Chuck Royce | 327,338 | $1,538,489 | -23% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.32 | 80,000 | Director | 100,000 | 2023-03-29 | Filing | |
| $11.12 | 20,000 | Director | 20,000 | 2021-11-22 | Filing | |
| $13.00 | 1,800,000 | Large Shareholder | 13,971,334 | 2021-07-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.41 | 5,000 | 120,583 | 2024-03-26 | Filing | ||
| $4.60 | 5,000 | 120,583 | 2024-02-26 | Filing | ||
| $5.12 | 5,000 | 120,583 | 2024-01-26 | Filing | ||
| $4.53 | 5,000 | Director | 120,583 | 2023-12-26 | Filing | |
| $5.17 | 99,442 | Officer, Director | 333,197 | 2023-12-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,341,386 | $34,504,514 | 0% | |
| 2. | 5,282,108 | $24,825,907 | 0% | |
| 3. | 5,043,356 | $23,703,773 | 6.02% | |
| 4. | 3,481,010 | $16,360,746 | 0% | |
| 5. | 2,833,715 | $13,318,460 | 0% |
News See All
Hedge Funds Say These Penny Stocks Are Poised to Explode
Despite common belief, not all penny stocks are inherently risky and suitable only for short-term gains.
MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by, and welcome to MaxCyte’s Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
MaxCyte, Inc. (NASDAQ:MXCT) Q2 2023 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to MaxCyte's Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by and welcome to MaxCyte’s First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2022 Earnings Call Transcript
Operator: Good day and thank you for standing by and welcome to MaxCyte's Fourth Quarter Earnings Conference Call. Please be advised that today's conference is being recorded.
Top 5 Stock Picks of Eli Casdin's Casdin Capital
In this article, we discuss the top 5 stock picks of Eli Casdin's Casdin Capital.
Should You Invest in MaxCyte (MXCT)?
Investment management company RGA Investment Advisors recently released its third-quarter 2022 investor letter. A copy of the same can be downloaded here.
Should You Invest in MaxCyte (MXCT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here.
Is it a Good Time to Dispose Your MaxCyte (MXCT) Shares?
Baron Funds, an asset management firm, published its “Baron Small Cap Fund” second quarter 2022 investor letter – a copy of which can be downloaded here.
Billionaire Hedge Funds
